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Abstract
Introduction: Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to be important in the
development of inflammatory models of rheumatoid arthritis and there is encouraging data that its blockade may
have clinical relevance in patients with rheumatoid arthritis. The aims of the current study were to determine
whether GM-CSF may also be important for disease and pain development in a model of osteoarthritis.
Methods: The role of GM-CSF was investigated using the collagenase-induced instability model of osteoarthritis.
We studied both GM-CSF-/- mice and wild-type (C57BL/6) mice treated prophylactically or therapeutically with a
monoclonal antibody to GM-CSF. Disease development (both early and late) was evaluated by histology and knee
pain development was measured by assessment of weight distribution.
Results: In the absence of GM-CSF, there was less synovitis and matrix metalloproteinase-mediated neoepitope
expression at week 2 post disease induction, and less cartilage damage at week 6. GM-CSF was absolutely required
for pain development. Therapeutic neutralization of GM-CSF not only abolished the pain within 3 days but also led
to significantly reduced cartilage damage.
Conclusions: GM-CSF is key to the development of experimental osteoarthritis and its associated pain. Importantly,
GM-CSF neutralization by a therapeutic monoclonal antibody-based protocol rapidly and completely abolished
existing arthritic pain and suppressed the degree of arthritis development. Our results suggest that it would be
worth exploring the importance of GM-CSF for pain and disease in other osteoarthritis models and perhaps
clinically for this form of arthritis.
Introduction
Granulocyte-macrophage colony-stimulating factor (GM-
CSF) was originally defined as a hemopoietic growth factor
[1]. However, it can act on mature myeloid cells [2] and it
has other functions, acting as a proinflammatory cytokine
[2-5] and in dendritic cell function [6]. More specifically,
its depletion can have profound effects on disease severity
and progression in many inflammatory arthritis models
[7-10]; encouragingly, initial results suggest that antibody
blockade of the GM-CSF receptor has therapeutic benefit
in rheumatoid arthritis (RA) [11,12].
Osteoarthritis (OA) is the most common rheumatic dis-
order. The pathogenic characteristics of OA are loss of
cartilage with associated underlying bony changes consist-
ing of sclerosis, subchondral bone collapse, bone cysts,
and osteophyte formation [13]. Pain is one of the most
important symptoms of OA as it causes a significant
impairment in function. The etiology of OA is likely to be
multifactorial, with mechanical, metabolic and inflamma-
tory contributions. Recent histologic evidence indicates
that synovitis can be an early feature in OA, even in joints
where it could not be detected clinically [14-16], with a
mixed inflammatory infiltrate consisting mainly of macro-
phages and with proinflammatory mediator production
(for example, TNF, IL-1b) [17,18]. It has been argued that* Correspondence: adcook@unimelb.edu.au1Arthritis and Inflammation Research Centre, Department of Medicine, The
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OA synovial inflammation is qualitatively similar to that in
RA, differing only in magnitude [19].
The collagenase-induced OA model is based on the
induction of joint instability by intra-articular injection of
collagenase. This causes weakening of the ligaments,
leading to an OA-like pathology, including cartilage
matrix erosion and osteophyte formation within 6 weeks
[20,21]. It is macrophage-dependent; the macrophages
mediate osteophyte formation and fibrosis in the early
stages [21,22]. Given that the major functions of GM-
CSF appear to be as a pro-survival and ‘activating’ factor
for myeloid cells [2], in the current study we investigated
whether this experimental OA model is dependent on
GM-CSF. As pain is an important symptom of OA, with
a complex relationship with tissue damage [23], the
requirement of GM-CSF for development of such pain in
the collagenase-induced arthritis model was also sought.
We have recently shown that GM-CSF is key to the
development of arthritic pain in a number of inflamma-
tory arthritis models [24].
We report here that GM-CSF is an important media-




GM-CSF gene-deficient (GM-CSF-/-) mice were back-
crossed onto the C57BL/6 background for 12 generations
[8,25,26]. Mice of both sexes, 8 to 12 weeks of age, were
used in all experiments. Mice were housed five per cage
and the male:female distribution was comparable for all
experimental groups. All experiments were approved by
The University of Melbourne Animal Ethics Committee.
Collagenase-induced arthritis
Arthritis was induced as published [21]. Briefly, mice
received an intra-articular injection of one unit of col-
lagenase type VII (Sigma-Aldrich, St. Louis, Missouri,
USA) on days 0 and 2 to induce joint instability. Because
of the focal nature of the damage seen in this model [27],
the region of the joint most affected (lateral or medial
side) is dependent on the placement of the initial injec-
tion (that is, from which side). This placement varied
between experiments but for individual experiments was
kept constant. Mice were sacrificed at weeks 1, 2 and 6
post collagenase injection and knee joints were collected
for histology.
Pain readings
As an indicator of knee pain, the differential distribution
of weight on the hind limbs was measured using an inca-
pacitance meter (IITC Life Science Inc., Woodland Hills,
CA, USA). This validated technique for arthritic knee
pain [24,28,29] measures changes in weight distribution
between the arthritic hind limb relative to the non-
arthritic hind limb. Mice were allowed to acclimatize to
the equipment on three occasions prior to experiment.
Weight placed on each limb was measured over a 5-sec-
ond period. Three separate measurements were taken per
mouse for each time point by an independent observer
without knowledge of the experimental groups. The read-
ings were then averaged. Results are expressed as a
percentage of the weight placed on the arthritic limb
verses the contralateral control limb (arthritic limb/con-
trol limb × 100). A decrease in weight applied to the
arthritic limb (that is, a reading <100) indicates pain [24].
Antibody treatment
Mice with collagenase-induced arthritis were treated by
intraperitoneal injection, either prophylactically or thera-
peutically, with anti-mouse GM-CSF monoclonal antibody
(mAb; MP1-22E9, AbD Serotec, Oxford, UK) or IgG2a
isotype control mAb (AbD Serotec) [7,10]. For prophylac-
tic treatment, mice were given 250 µg per mouse per treat-
ment of anti-GM-CSF or control mAb beginning 4 days
prior to the first collagenase injection (day 0), with subse-
quent treatment on days -2 and 0, and thereafter three
times per week for 6 weeks. Serum samples were collected
at 2, 4 and 6 weeks post collagenase injection and investi-
gated for their anti-GM-CSF mAb concentration. High
serum levels of MP1-22E9 were detected at each time
point, which, in the light of published potency data on
MP1-22E9 [30], prompted us to reduce the dose used and
extend the dosing intervals for the therapeutic treatment.
For therapeutic treatment, mice were given 150 µg per
mouse per treatment of anti-GM-CSF or control mAb
twice per week following the onset of pain, until the end
of the experiment at 6 weeks. The onset of pain was
defined as a significant difference in the average pain com-
pared with t = 0.
Histology
At termination after arthritis induction, the knee joints
were removed, fixed, decalcified, and paraffin embedded,
as previously described [7,10]. Frontal sections (5 µm)
were stained with either H & E to examine joint architec-
ture or with safranin O, fast green and hematoxylin for
proteoglycan loss, and evaluated by two independent
observers without knowledge of the experimental groups,
using the histologic assessment as follows.
Week 1 and 2 sections were scored for cellular infiltra-
tion and synovial hyperplasia from 0 (normal) to 3
(severe) as previously [21]. Week 6 sections were scored
for cartilage damage in terms of the OA depth into carti-
lage (grade) and amount of cartilage affected (stage), as
described by van Lent et al. [31]. This scoring system is
modified from that of Pritzker et al. [32] to make it more
suitable for measuring pathologic changes in murine
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cartilage. OA grade was scored from 0 (normal) to 6
(bone loss, remodeling, deformation) and OA stage from
0 (<10% involvement) to 4 (>50% involvement) for the
lateral tibia, lateral femur, medial tibia, and medial femur.
The grade and stage were then multiplied to give an
overall OA score, to represent a combined assessment of
OA severity and extent [31]. Up to six sections were
scored per mouse, and an average taken. Safranin
O-stained sections were used to assess the presence of
osteophytes at the lateral and medial femur and tibia.
Their size was analyzed using the image software Image J
(National Institutes of Health, Bethesda, MD, USA ). The
mean area per knee joint (three sections) was calculated
and expressed in arbitrary units.
Immunohistochemistry
The matrix metalloproteinase (MMP)-induced neoepitope,
DIPEN, was detected as published [33]. Briefly, paraffin-
embedded sections were deparaffinized and rehydrated,
and endogenous peroxidise blocked with 3% (vol/vol)
H2O2 (Sigma-Aldrich). Sections were digested with chon-
droitinase ABC (0.1 units/mL; Sigma-Aldrich) for 2 hours
at 37°C to remove chondroitin sulfate from the proteogly-
cans, prior to blocking with 5% goat serum. Sections were
then incubated overnight at 4°C with anti-DIPEN [34] (a
gift from A/Professor Amanda Fosang, University of
Melbourne, Victoria, Australia) and detected with a bioti-
nylated anti-rabbit IgG (Dako, Glostrup, Denmark),
followed by a streptavidin-peroxidase conjugate (BD Bio-
sciences, San Jose, CA, USA). Peroxidase activity was
demonstrated by incubation with 3,3’-diaminobenzidine/
tetrahydrochloride (Sigma-Aldrich)-H2O2 solution. Slides
were counterstained with hematoxylin.
DIPEN staining was scored from 0 to 3 based on
amount of staining, where 0 = no staining and 3 = max-
imal staining, as previously described [35].
Statistics
For pain readings, Student’s t-test or two-way analysis of
variance was used. For histologic scores, the Mann-Whit-
ney two-sample rank test or two-way analysis of variance
was used; values are expressed as the mean ± standard
error of the mean. P * 0.05 was considered statistically
significant.
Results
GM-CSF is important throughout collagenase-induced
arthritis progression
Several RA-like inflammatory arthritis models have been
shown to be GM-CSF dependent [7-10]. To determine
whether an OA-like model was also dependent on GM-
CSF, histology was performed on the joints of C57BL/6
(wild-type) and GM-CSF-/- mice at 6 weeks post collage-
nase intra-articular injection and disease scored according
to the published protocol [31]. At this time point, synovitis
was not evident (data not shown). GM-CSF-/- mice
showed less knee joint tissue damage in the lateral tibia
(P = 0.003), lateral femur (P = 0.02) and medial tibia (P =
0.001) compared with wild-type mice (Figure 1A,B). Over-
all the mean arthritis score for all regions was significantly
lower in GM-CSF-/- mice compared with that in wild-
type mice (P = 0.002) (Figure 1B).
Synovitis and osteophyte formation have previously been
reported to be present early in disease development in this
model [21]. Therefore, a role for GM-CSF in the develop-
ment of these disease features was examined at 1 and 2
weeks post collagenase injection. Mild synovitis was
observed in wild-type mice at both time points (Figure 2A,
B); however, this was virtually absent in GM-CSF-/- mice
with only one mouse at week 1 having a very low score.
Expression of the MMP-generated proteoglycan neoepi-
tope, DIPEN, was assessed by immunohistochemistry as a
measure of MMP-mediated cartilage damage [36]. At
week 2, there was significantly greater expression of the
neoepitope in the cartilage of wild-type mice compared
with that in GM-CSF-/- mice (P = 0.02; Figure 2C,D). At
both 1 and 2 weeks, there was a trend towards there being
fewer osteophytes in GM-CSF-/- mice compared with
wild-type mice, and a trend towards the mean osteophyte
size being smaller in the former strain (data not shown).
Therefore, GM-CSF plays a role throughout the arthritis
progression in this model.
Collagenase-induced arthritis pain is GM-CSF dependent
We have recently shown that GM-CSF is key to the devel-
opment of arthritic pain in a number of inflammatory
arthritis models [24]. We next explored whether GM-CSF
was critical also for joint pain development in this OA-like
model by administering a neutralizing mAb to GM-CSF
prophylactically. Pain has not been recorded in this model.
Pain was measured by the changes in weight distribution
using an incapacitance meter and has been validated pre-
viously to measure arthritic knee pain [24,28,29]. To assess
whether there is pain induction, C57BL/6 mice received
control mAb beginning 4 days prior to collagenase injec-
tion. Knee pain was evident from around 3 weeks and
remained significant until 6 weeks when the mice were
sacrificed (Figure 3A). Mice pretreated with anti-GM-CSF
mAb, however, did not develop any detectable pain. From
around day 22, control mAb-treated mice showed signifi-
cantly more pain compared with anti-GM-CSF mAb-
treated mice (P < 0.05).
In agreement with the GM-CSF-/- mouse arthritis
data above, at 6 weeks the anti-GM-CSF mAb-treated
mice also had significantly less arthritis in the lateral
femur (P = 0.03) and medial femur (P = 0.004), com-
pared with the control mAb-treated group (Figure 3B).
To confirm that the isotype control mAb had no effect
Cook et al. Arthritis Research & Therapy 2012, 14:R199
http://arthritis-research.com/content/14/5/R199
Page 3 of 9
on disease development, a PBS control group was also
included. There was no significant difference in the his-
tologic scores for the PBS-treated group and the control
mAb-treated group for any of the regions scored (data
not shown).The mean level of arthritis development was
significantly lower in the anti-GM-CSF mAb-treated
group (P = 0.003). Once again, synovitis could not be
detected at this time point in any of the mice, and in
mice where osteophytes were detected, they were signifi-
cantly smaller in the anti-GM-CSF mAb-treated group
compared with the control mAb-treated group (mean
size: anti-GM-CSF mAb-treated group, 238 ± 114 versus
control mAb-treated group, 577 ± 48, P < 0.05).
Thus GM-CSF is an essential mediator of knee pain
progression in this OA-like model.
Therapeutic neutralization of GM-CSF ameliorates both
collagenase-induced arthritic pain and disease
development
The mAb-based approach allowed us to next determine
whether therapeutic treatment with anti-GM-CSF mAb
could also suppress the pain and disease, and how rapidly
it might reverse the pain. Once knee pain was evident in
collagenase-injected C57BL/6 mice, those with similar
pain readings were treated with either control mAb or
anti-GM-CSF mAb twice weekly until week 6. Treatment
with the control mAb had no effect on the pain, which
continued to increase (Figure 4A). Treatment with anti-
GM-CSF mAb completely suppressed the pain within 3
days, this being the earliest time at which it was measured
following mAb treatment. This abolition of knee pain was
maintained until sacrifice (day 42). By histology, at 6
weeks the anti-GM-CSF mAb-treated mice also had signif-
icantly milder disease in the medial tibia (P < 0.01) and
medial femur (P < 0.05) regions of the joints (Figure 4B,C)
with the mean level of arthritis development also being
significantly lower in the anti-GM-CSF mAb-treated
group for this therapeutic treatment protocol. Once again,
in mice where osteophytes were detected, they were signif-
icantly smaller following anti-GM-CSF mAb treatment as
compared with control mAb treatment (mean size: 267 ±
17 versus 406 ± 14, P < 0.05).
Discussion
We demonstrated above for the first time that GM-CSF is
required for both pain and optimal disease development in
a joint instability OA model. Furthermore, GM-CSF neu-
tralization by a therapeutic mAb-based protocol rapidly
and completely abolished existing arthritic pain. Experi-
mental OA, induced by intra-articular collagenase injec-
tion as above, has been shown to share some important
features with human OA, such as the development of
osteophytes and cartilage erosion [20,21]. There is also a
low grade inflammatory response (synovitis), which can
also be seen in the human disease [37]. The mild synovitis
observed early in disease development was virtually absent
when GM-CSF was not present. This is in agreement with
previous studies using systemic inflammatory models of
Figure 1 GM-CSF is required for optimal expression of collagenase-induced arthritis. Arthritis was initiated in C57BL/6 and GM-CSF-/- mice
by intra-articular collagenase injection (Methods) and histology performed 6 weeks later. (A) Representative histologic pictures of knee joints
(Safranin O/fast green stain) (original magnification ×100). (B) Quantification of arthritis development (histology) at day 42 (Methods). Results are
expressed as the mean ± standard error of the mean; n = 10 mice per strain (from two independent experiments). *P < 0.05, **P < 0.01, ***P <
0.001, GM-CSF-/- versus C57BL/6 mice. C: cartilage; GM-CSF: granulocyte-macrophage colony-stimulating factor; LF: lateral femur; LT: lateral tibia;
M: meniscus; MF: medial femur; MT: medial tibia; arrow indicates cartilage damage.
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Figure 2 GM-CSF is required for optimal synovitis and cartilage breakdown associated with collagenase-induced arthritis. Arthritis was
initiated in C57BL/6 and GM-CSF-/- mice by intra-articular collagenase injection and histology performed 1 and 2 weeks later. (A) Representative
histologic pictures of knee joints at 2 weeks (original magnification ×100). (B) Quantification of synovitis. (C) Representative DIPEN staining in
knee joints at 2 weeks (original magnification ×125). (D) Quantification of DIPEN staining. Results are expressed as the mean ± standard error of
the mean; n = 5 to 8 mice per strain per time point (from two independent experiments).*P = 0.05, **P = 0.02, ***P = 0.002, GM-CSF-/- versus
C57BL/6 mice. C: cartilage; F: femur; GM-CSF: granulocyte-macrophage colony-stimulating factor M: meniscus; O: osteophyte; T: tibia.
Figure 3 Pain in collagenase-induced arthritis is GM-CSF dependent. C57BL/6 mice were treated prophylactically (from day -4) with anti-
GM-CSF or isotype control monoclonal antibody. (A) Change in weight distribution (pain) (Methods) over time. (B) Quantification of arthritis
development (histology) at day 42. Results are expressed as the mean ± standard error of the mean; n = 10 to 15 mice per group (from two
independent experiments). *P <0.05, **P <0.01, ***P <0.001, control versus anti-GM-CSF. GM-CSF: granulocyte-macrophage colony-stimulating
factor; LF: lateral femur; LT: lateral tibia; MF: medial femur; MT: medial tibia.
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arthritis in which blockade or absence of GM-CSF led to a
reduced inflammatory response and fewer macrophages in
the joint [8,10]. Synovial macrophages have been shown to
be important in this OA-like model, with both synovial
inflammation and cartilage damage being ameliorated
when they are selectively depleted from the synovial lining
layer by clodronate liposomes [21]. As GM-CSF can
directly promote macrophage survival [38], its neutraliza-
tion may also lead to direct depletion of joint macro-
phages, in this case by apoptosis [38]. In the current study,
the degree of MMP-mediated cartilage damage was also
lower in the absence of GM-CSF, suggesting that GM-CSF
may be important for sustained and ongoing joint damage,
possibly by limiting synovial macrophage activation in
addition to their numbers [2,4,38].
Osteophyte formation, which is a common feature of
OA and which may be a repair mechanism to help
stabilize joints [39], is prevented by synovial macrophage
depletion in the collagenase-induced model [21]. An asso-
ciation between osteophytes and pain has been reported
for hand OA [40]. In the absence of GM-CSF, the size of
the osteophytes formed was smaller than in the presence
of GM-CSF. This may be related to the lack of pain seen
in the absence of GM-CSF. It could also indicate some
requirement of (GM-CSF dependent) synovitis for osteo-
phyte development, as has been previously suggested [41];
however, given there was still some osteophyte formation
present in GM-CSF-/- mice, other factors may also be
important, such as transforming growth factor b [42]. The
degree of cartilage damage seen at 6 weeks post collage-
nase injection in the absence of GM-CSF was significantly
decreased compared with that in wild-type mice. Interest-
ingly, antibody-mediated GM-CSF blockade both pre-
vented (prophylactic treatment) and reversed completely
Figure 4 Therapeutic neutralization of GM-CSF reverses collagenase-induced arthritis pain and disease. C57BL/6 mice were treated
therapeutically (from day 20) with either anti-GM-CSF or isotype control monoclonal antibody. (A) Change in weight distribution (pain) over
time. (B) Quantification of arthritis development (histology) at day 42. (C) Representative histologic pictures of knee joints (safranin O/fast green
stain) (original magnification ×100), arrow indicates cartilage damage. Results are expressed as the mean ± standard error of the mean; n = 10 to
15 mice per group (from two independent experiments). *P <0.05, **P <0.01, ***P <0.001, control versus anti-GM-CSF; # P<0.0001, control and
anti-GM-CSF versus t = 0 readings. C: cartilage; GM-CSF: granulocyte-macrophage colony-stimulating factor; LF: lateral femur; LT: lateral tibia; M:
meniscus; MF: medial femur; MT: medial tibia.
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(therapeutic treatment) the arthritic pain and modulated
the degree of osteoarthritic changes in the joint, indicating
that GM-CSF is important both in the early and late stages
in this model, even though the features of the model
change over time. Of note, the neutralization of GM-CSF
abolished existing pain within 3 days, the earliest time
point measured. The effectiveness of the therapeutic pro-
tocol was similar to the findings for disease progression in
systemic inflammatory and autoimmune models [7,10]. In
addition to its direct effects on macrophages, GM-CSF
may also have direct effects on neuronal sensitization in
the OA lesion, similar to that suggested by Schweizerhof
et al. [43] for bone cancer pain. Knee pain was evident 3
weeks post collagenase injection. The synovitis seen early
in disease development in wild-type mice thus did not
lead to any detectable pain, that is, a difference in weight
distribution, unlike in more severe inflammatory models
of arthritis [24,28,29]. This observation fits with the mild
nature of the inflammatory response in this model. It
would be of interest to determine the degree of synovitis
at 3 weeks post collagenase injection, at the time of detect-
able pain, and to determine the effect of GM-CSF block-
ade at this time point on the synovitis. Recently, van Lent
et al. [31] showed that synovitis peaks at week 2 in this
model, before we were able to detect pain, further suggest-
ing that the synovitis alone is unlikely to account for the
pain. Exactly how GM-CSF is acting at the different stages
is currently being investigated.
For the collagenase-induced model, cartilage damage is
also less in IL-1b-/- mice [44], suggesting a link between
GM-CSF and IL-1. Such a link has been found before
with the GM-CSF dependence of an IL-1b-induced
inflammatory monoarthritis model [8,24], consistent with
the concept of a ‘colony-stimulating factor network’ link-
ing GM-CSF, IL-1, and other cytokines [2,4,45]. That
such a link between IL-1 and GM-CSF may also be oper-
ating in the collagenase-induced arthritis model is sup-
ported by the fact that IL-1 can enhance MMP-mediated
DIPEN neoepitope expression in cartilage [46], similar to
our data above for GM-CSF and neoepitope expression.
Conclusions
From the above findings, it is proposed that GM-CSF is a
key mediator of both pain and disease development in an
experimental model of OA, in addition to its known role
(s) in RA models. Both prophylactic and therapeutic
blockade of GM-CSF were effective at ameliorating both
pain and disease. Results from clinical trials assessing the
role of GM-CSF in RA are encouraging [11,12]. Our
results here suggest that it would be worth exploring the
importance of GM-CSF for the pain and disease in other
OA models and perhaps clinically for this form of
arthritis.
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